LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy

Eli Lilly (LLY) secured significant regulatory advancements, receiving EU marketing authorization for Kisunla (donanemab) to treat early symptomatic Alzheimer's disease, based on clinical data demonstrating it significantly slowed cognitive and functional decline. Concurrently, the FDA approved Inluriyo (imlunestrant) for advanced or metastatic ER+, HER2- breast cancer with ESR1 mutations, following evidence from the EMBER-3 study showing a 38% reduction in the risk of progression or death. These dual approvals bolster Lilly's pipeline and market position in critical therapeutic areas.

Analysis

Eli Lilly has secured two significant regulatory approvals that bolster its neurology and oncology franchises. The European Commission's marketing authorization for Kisunla (donanemab) opens up the EU market for its early symptomatic Alzheimer's disease treatment, backed by TRAILBLAZER study data demonstrating a significant slowdown in cognitive and functional decline. This positions Kisunla to compete directly with Biogen's Leqembi, which operates on a similar amyloid-beta reduction mechanism. Early commercial indicators appear positive, with Kisunla generating $70.1 million in sales in the first half of 2025, suggesting a steady launch trajectory. Concurrently, the FDA's approval of Inluriyo (imlunestrant) for a specific subset of advanced breast cancer (ER+, HER2–, ESR1-mutated) adds a new revenue stream in the near term, with a US launch planned in the coming weeks. The approval is supported by strong efficacy from the EMBER-3 study, which showed a 38% reduction in the risk of disease progression or death. Despite these positive fundamental developments, Lilly's stock has underperformed, declining 7.4% year-to-date against a 0.5% decrease for its industry, which may indicate that this news was already priced in or that other market factors are weighing on the shares.

Key Decisions for Investors

• Investors should re-evaluate valuation models for Eli Lilly to account for the newly approved revenue streams from Kisunla in the EU and Inluriyo in the US, which de-risk its late-stage pipeline.
• Monitor the commercial uptake and market share of Kisunla against its primary competitor, Biogen's Leqembi, as this will be a critical determinant of its long-term value in the Alzheimer's market.
• Consider the disconnect between the positive regulatory news and the stock's 7.4% year-to-date underperformance, as this could signal a potential buying opportunity if the market has not fully digested the long-term earnings impact.
• Note the embryo-fetal toxicity warning on Inluriyo's label as a potential risk factor that could influence its prescription rate and commercial success in the competitive oncology space.